Jonathan R Strosberg

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi request reprint Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas
    Jonathan Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Pancreas 38:255-8. 2009
  2. ncbi request reprint Targeting AKT protein kinase in gastric cancer
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Anticancer Res 31:4387-92. 2011
  3. ncbi request reprint Evolving treatment strategies for management of carcinoid tumors
    Jonathan Strosberg
    Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, 33612, USA
    Curr Treat Options Oncol 14:374-88. 2013
  4. pmc A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors
    J R Strosberg
    Department of GI Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    Endocr Relat Cancer 20:383-90. 2013
  5. ncbi request reprint Neuroendocrine tumours of the small intestine
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Dept of GI Oncology, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Best Pract Res Clin Gastroenterol 26:755-73. 2012
  6. ncbi request reprint Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma
    Jonathan R Strosberg
    Gastrointestinal and Neuroendocrine Tumor Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Semin Oncol 40:120-33. 2013
  7. ncbi request reprint Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 31:420-5. 2013
  8. ncbi request reprint A phase II study of RO4929097 in metastatic colorectal cancer
    Jonathan R Strosberg
    Dept of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    Eur J Cancer 48:997-1003. 2012
  9. ncbi request reprint A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
    J R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Ann Oncol 23:2335-41. 2012
  10. ncbi request reprint Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Ann Surg 256:321-5. 2012

Detail Information

Publications34

  1. ncbi request reprint Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas
    Jonathan Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Pancreas 38:255-8. 2009
    ..Our objective was to evaluate the stage-specific prognosis of patients with metastatic PECAs and to assess the impact of clinical and pathologic prognostic factors...
  2. ncbi request reprint Targeting AKT protein kinase in gastric cancer
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Anticancer Res 31:4387-92. 2011
    ..In this article, we will review the current knowledge on AKT signaling in the pathogenesis of gastric cancer and the evolving therapeutic implications of targeting this pathway...
  3. ncbi request reprint Evolving treatment strategies for management of carcinoid tumors
    Jonathan Strosberg
    Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, 33612, USA
    Curr Treat Options Oncol 14:374-88. 2013
    ..This article reviews the evolving treatment strategies for metastatic carcinoid tumors of the aerodigestive tract, with a focus on new systemic targeted agents and liver-directed therapies...
  4. pmc A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors
    J R Strosberg
    Department of GI Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    Endocr Relat Cancer 20:383-90. 2013
    ..Although well tolerated, treatment with single-agent ganitumab failed to result in significant tumor responses among patients with metastatic well-differentiated carcinoid or pNET...
  5. ncbi request reprint Neuroendocrine tumours of the small intestine
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Dept of GI Oncology, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Best Pract Res Clin Gastroenterol 26:755-73. 2012
    ..This article examines the biological characteristics of small intestinal NETs, summarizes current guidelines on classification, staging and grading, and reviews developments in locoregional and systemic therapy...
  6. ncbi request reprint Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma
    Jonathan R Strosberg
    Gastrointestinal and Neuroendocrine Tumor Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Semin Oncol 40:120-33. 2013
    ..In this update on management of unusual neuroendocrine tumors, we review the biology and treatment of these rare neoplasms...
  7. ncbi request reprint Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 31:420-5. 2013
    ..This classification has not been validated in a population consisting solely of midgut NETs. The purpose of this study was to test the prognostic validity of the classification in such a population...
  8. ncbi request reprint A phase II study of RO4929097 in metastatic colorectal cancer
    Jonathan R Strosberg
    Dept of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    Eur J Cancer 48:997-1003. 2012
    ..RO4929097 is a selective inhibitor of γ-secretase. We tested the activity of RO4929097 in patients with metastatic, refractory colorectal cancer...
  9. ncbi request reprint A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
    J R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Ann Oncol 23:2335-41. 2012
    ..We hypothesized that administration of sunitinib, a VEGFR inhibitor, following TAE would extend progression-free survival (PFS)...
  10. ncbi request reprint Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Ann Surg 256:321-5. 2012
    ....
  11. ncbi request reprint First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:268-75. 2011
    ..The authors retrospectively evaluated the efficacy of capecitabine and temozolomide in 30 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS), and overall survival (OS)...
  12. ncbi request reprint Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors
    Jonathan R Strosberg
    Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, USA
    J Clin Oncol 29:3044-9. 2011
    ..This classification has not yet been validated...
  13. ncbi request reprint A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 18:127-37. 2011
    ..New evidence demonstrates that these agents can also inhibit tumor growth. Other novel agents targeting the VEGF and mTOR pathways have recently been investigated in multicenter phase III studies...
  14. ncbi request reprint Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Hum Pathol 40:1262-8. 2009
    ..Both mitotic rates and Ki-67 indexes are inversely associated with survival and can be analyzed independently for assignment of grade...
  15. ncbi request reprint Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33629, USA
    Neuroendocrinology 89:471-6. 2009
    ..Past analyses of survival suggest a trend towards improving longevity among patients with metastatic mid-gut NETs...
  16. pmc External beam irradiation of myocardial carcinoid metastases: a case report
    Jonathan Strosberg
    H, Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Med Case Reports 1:95. 2007
    ..To our knowledge, this is the first reported case of metastatic cardiac carcinoid treated with external beam irradiation...
  17. ncbi request reprint Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors
    Jonathan R Strosberg
    Hematology Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Cancer Control 13:72-8. 2006
    ..Several reviews have suggested that hepatic artery embolization, with or without intraarterial chemotherapy, can be used for control of symptoms and for cytoreduction in patients with liver dominant metastases...
  18. ncbi request reprint Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes
    Asima Cheema
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Ann Surg Oncol 19:2932-6. 2012
    ..The frequency of incidental detection is unknown. It is also unclear whether patients with incidentally discovered, early-stage, asymptomatic tumors should be treated similarly to patients who present with tumor-related symptoms...
  19. pmc Multimodality approach for locally advanced esophageal cancer
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    World J Gastroenterol 18:5679-87. 2012
    ..The role of adjuvant chemotherapy following curative resection is still unclear. External beam radiation therapy alone is considered palliative and is typically reserved for patients with a poor performance status...
  20. ncbi request reprint Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Pancreas 42:397-404. 2013
    ..This study aimed to develop expert consensus for the use of systemic treatments for unresectable metastatic well-differentiated (grade 1-2) carcinoid tumors using the RAND/UCLA modified Delphi process...
  21. ncbi request reprint A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours
    Jonathan R Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Expert Opin Investig Drugs 16:219-24. 2007
    ..This review summarises the present scope of clinical research in this field...
  22. ncbi request reprint Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors
    Dana A Osborne
    Digestive Disorders Center, Tampa General Hospital, 1 Davis Island, Tampa, Florida 33601, USA
    Ann Surg Oncol 13:572-81. 2006
    ..The purpose of this study was to determine whether cytoreduction provides any benefit over embolic management of diffuse neuroendocrine tumors...
  23. ncbi request reprint Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?
    Pamela J Hodul
    Gastrointestinal Tumor Program, Departmentsof Surgery, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:314-21. 2008
    ..This paper discusses whether aggressive surgical intervention is indicated for PNETs and investigates what prognostic factors may assist in predicting which patients with invasive disease will benefit most from surgical intervention...
  24. ncbi request reprint Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver
    Larry K Kvols
    Neuroendocrine Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 7:765-72. 2009
    ..In this article, the authors examine important techniques in the armamentarium of the interventional radiologist...
  25. ncbi request reprint Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels
    Aejaz Nasir
    Department of Interdisciplinary Oncology, Neuroendocrine Cancer Research Group, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Pancreas 36:309-13. 2008
    ..In summary, this is a unique case of metastatic VIP- and calcitonin-secreting pancreatic ECA with dramatic sustained clinical, biochemical, and objective tumor response to peptide receptor radionuclide therapy...
  26. ncbi request reprint Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    James S Barthel
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Gastrointest Endosc 71:235-40. 2010
    ..The response of esophageal adenocarcinoma to chemoradiation therapy is well described; however, the effect of chemoradiation on tumor-associated BE has not been specifically reported...
  27. pmc Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour
    Jonathan R Strosberg
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Can J Gastroenterol 21:113-5. 2007
    ..To the authors' knowledge, this is the first case presentation of chronic, partial small bowel obstruction caused by unrecognized retention of a capsule endoscope...
  28. ncbi request reprint Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA Analysis Group, Inc, Boston, Massachusetts, USA Department of Internal Medicine, University of South Florida, Tampa, Florida, USA Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 19:930-6. 2014
    ....
  29. ncbi request reprint Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience
    Joyce Wong
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Am J Surg 208:775-80. 2014
    ..Staging for pancreatic neuroendocrine tumors (PNET) considers tumor size and lymph node (LN) status; however, correlation with survival remains unclear...
  30. ncbi request reprint Familial Gastrointestinal Stromal Tumor Syndrome: Report of 2 Cases With KIT Exon 11 Mutation
    Derek H Jones
    Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 22:102-8. 2015
    ..As with cases of sporadic gastrointestinal stromal tumor (GIST), familial GIST syndrome arises from mutations in KIT or PDGFRA. Only a few dozen such families have been described in the literature...
  31. pmc The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Pancreas 39:799-800. 2010
    ..In patients with localized tumors undergoing surgical resection, adjuvant treatment (chemotherapy with or without radiation) is warranted in most cases...
  32. pmc Biology and treatment of metastatic gastrointestinal neuroendocrine tumors
    Jonathan R Strosberg
    Department of GI Oncology, H Lee, Moffitt Cancer Center, Tampa, FL
    Gastrointest Cancer Res 2:113-25. 2008
    ..This article reviews the diverse biologic characteristics of gastrointestinal neuroendocrine tumors and current treatment options for metastatic disease...
  33. ncbi request reprint Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Fla, USA
    Neuroendocrinology 85:216-20. 2007
    ....
  34. ncbi request reprint Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility
    Aejaz Nasir
    Gastrointestinal Tumor Program, Neuroendocrine Cancer Research, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Cancer Control 13:52-60. 2006
    ..In patients with SSTR-negative ETs, the clinical response is generally absent or suboptimal, while nonfunctioning ETs with SSTR positivity show a variable response to such therapy...